Marimed (MRMD) Common Equity (2011 - 2026)

Marimed (MRMD) has 16 years of Common Equity data on file, last reported at $46.5 million in Q1 2026.

• On a quarterly basis, Common Equity fell 19.56% year-over-year to $46.5 million in Q1 2026; TTM through Mar 2026 was $46.5 million, a 19.56% decrease from a year earlier, with the FY2025 full-year figure at $50.0 million, down 14.58% from the prior year.
• Common Equity for Q1 2026 stood at $46.5 million, down from $50.0 million in the prior quarter.
• Over the last five years, Common Equity for MRMD reached as high as $80.9 million in Q2 2023 and fell as low as $1.1 million in Q3 2025.
• Historically, Common Equity has averaged $57.0 million across 5 years, with a median of $57.8 million in 2025.
• Across the five-year window, Common Equity jumped 196.47% in 2022 and slumped 98.37% in 2025, its largest moves.
• Year by year, Common Equity stood at $57.3 million in 2022, then gained by 20.2% to $68.9 million in 2023, then slipped by 15.01% to $58.5 million in 2024, then retreated by 14.58% to $50.0 million in 2025, then fell by 6.99% to $46.5 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $46.5 million in Q1 2026, $50.0 million in Q4 2025, and $1.1 million in Q3 2025.